These and other risks are described in the reports filed by Achillion with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2018, and any other SEC filings that Achillion makes from time to time. In addition, any forward-looking statement in this press release represents Achillion's views only as of the date of this press release and should not be relied upon as representing its views as of any subsequent date. Achillion disclaims any duty to update any forward-looking statement, except as required by applicable law. Investors: Brian Di Donato Senior VP, Chief Financial Officer Tel. (215) 709-3032 bdidonato@achillion.com Media: Susanne Heinzinger Senior VP, Corporate Communications Tel. (215) 709-3055 sheinzinger@achillion.com Source: Achillion Pharmaceuticals, Inc.